New drug combo tested in Tough-to-Treat skin cancer
NCT ID NCT04109456
Summary
This early-stage study tested a new drug called IN10018, both alone and in combination with other cancer drugs, in 51 adults with advanced melanoma that had spread. The main goal was to check the safety of these treatments and see how the body processes the drug. Researchers also looked for early signs that the treatments could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Linear Clinical Research
Nedlands, Western Australia, Australia
-
MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
St Vincent Hospital Sydney
Sydney, New South Wales, Australia
-
Sylvester Comprehensive Cancer Center.
Miami, Florida, 33136, United States
-
The Alfred Hospital
Melbourne, Victoria, Australia
Conditions
Explore the condition pages connected to this study.